Thompson Peter A. 4
4 · Sionna Therapeutics, Inc. · Filed Apr 21, 2026
Research Summary
AI-generated summary of this filing
Sionna (SION) Director Peter A. Thompson Sells 55,345 Shares
What Happened
Peter A. Thompson, a director of Sionna Therapeutics, sold a total of 55,345 shares in two transactions: 52,397 shares on 2026-04-17 at $44.68 each ($2,341,098) and 2,948 shares on 2026-04-18 at $44.52 each ($131,245), for combined proceeds of approximately $2,472,343. These were sales (not purchases) and were reported on a Form 4 filed 2026-04-21.
Key Details
- Transaction dates and prices:
- 2026-04-17 — 52,397 shares sold at $44.68 ($2,341,098)
- 2026-04-18 — 2,948 shares sold at $44.52 ($131,245)
- Total shares sold: 55,345; total proceeds: ~$2.47M.
- Shares owned after transaction: not specified in the provided filing.
- Notable footnotes:
- F1: Sales were made pursuant to a 10b5‑1 trading plan.
- F2–F3: The shares are held of record by OrbiMed Private Investments VIII, LP. OrbiMed Advisors and related entities are noted as having potential voting/investment power; the reporting person is a member of OrbiMed Advisors and the parties disclaim beneficial ownership except to the extent of any pecuniary interest.
- Timeliness: Form 4 was filed 2026-04-21 for trades dated 2026-04-17 and 2026-04-18; this filing appears to be within the standard SEC two-business-day reporting window.
Context: These are director sales under a pre-established 10b5‑1 plan, which are commonly used to execute routine dispositions and do not on their own indicate the director’s view of the company’s prospects. The filing involves institutional record ownership through OrbiMed entities with disclaimers about beneficial ownership.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-04-17$44.68/sh−52,397$2,341,098→ 2,967,722 total(indirect: See footnotes) - Sale
Common Stock
[F1][F2][F3]2026-04-18$44.52/sh−2,948$131,245→ 2,964,774 total(indirect: See footnotes)
Footnotes (3)
- [F1]These securities were sold pursuant to a 10b5-1 plan.
- [F2]These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors.
- [F3]Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.